Drugie życie psychodelików
Krystyna Gołembiowska, K. Kamińska
Kosmos August 8, 2024 DOI: 10.36921/kos.2024_2994 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | Classic psychedelics have psychoplastogenic properties that suggest potential for treating depression, Alzheimer's disease, stroke recovery, and schizophrenia, but microdosing requires further investigation. |
Abstract
Psychedelics known for mankind from millennia are class of compounds that alter consciousness, affect perception and produce hallucinations. Classic psychedelics such as psilocybin, mescaline, dimethyltryptamine (DMT) and lysergic acid diethylamide (LSD) have pharmacodynamic serotonergic effects. They are known to exert profound effects on neuroplasticity i.e. alteration of neuronal structure and function. The psychoplastogenic properties led to their potential in treatment of depression, neurodegenerative disorders such as Alzheimer’s Disease, recovery after stroke and in schizophrenia. The role of microdosing regarded as 10% of the dose that elicits psychedelic effects needs extensive investigation.